In Vitro and In Vivo Efficacies of the EGFR/MEK/ERK Signaling Inhibitors in the Treatment of Alveolar Echinococcosis-Reference-Cited by-同舟云学术

In Vitro and In Vivo Efficacies of the EGFR/MEK/ERK Signaling Inhibitors in the Treatment of Alveolar Echinococcosis

Published:2020-07-22 Issue:8 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Cheng Zhe¹²,Xu Zhijian¹²,Tian Huimin³,Liu Fan³,Li Xiu¹²,Luo Damin¹²,Wang Yanhai¹²^ORCID

Affiliation:

1. State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, Fujian, China

2. Parasitology Research Laboratory, School of Life Sciences, Xiamen University, Xiamen, Fujian, China

3. Medical College, Xiamen University, Xiamen, Fujian, China

Abstract

Alveolar echinococcosis (AE), caused by the larval stage of the cestode Echinococcus multilocularis , is a lethal disease in humans. Novel therapeutic options are urgently needed since the current chemotherapy displays limited efficiency in AE treatment. In this study, we assessed the in vitro and in vivo effects of the epidermal growth factor receptor (EGFR)/MEK/extracellular signal-regulated kinase (ERK) signaling inhibitors, including BIBW2992, CI-1033, and U0126, on E. multilocularis .

Funder

National Parasitic Resources Center

National Natural Science Foundation of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00341-20

Reference37 articles.

1. Echinococcosis: Advances in the 21st Century

2. Clinical features and treatment of alveolar echinococcosis